COMETRIQ Drug Patent Profile

When do Cometriq patents expire, and what generic alternatives are available?

Cometriq is a drug marketed by Exelixis and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and ninety patent family members in thirty-one countries.

The generic ingredient in COMETRIQ is cabozantinib s-malate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.

DrugPatentWatch^® Generic Entry Outlook for Cometriq

Cometriq was eligible for patent challenges on November 29, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 10, 2032. This may change due to patent challenges or generic licensing.

There have been fourteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for COMETRIQ

International Patents:	190
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for COMETRIQ

US Patents and Regulatory Information for COMETRIQ

COMETRIQ is protected by eight US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-001	Nov 29, 2012		RX	Yes	No			Y	Y
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-001	Nov 29, 2012		RX	Yes	No			Y	Y
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-001	Nov 29, 2012		RX	Yes	No			Y
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-002	Nov 29, 2012		RX	Yes	Yes			Y

International Patents for COMETRIQ

When does loss-of-exclusivity occur for COMETRIQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Denmark

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering COMETRIQ around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2758030
Hong Kong	1164305
Australia	2012214322
South Korea	20200137052	암의 치료를 위한 Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-Ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 (----4-----11- MALATE SALT OF N-4-[67-BISMETHYLOXYQUINOLIN-4-YL]OXYPHENYL-N'-4-FLUOROPHENYLCYCLOPROPANE-11-DICARBOXAMIDE AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER)

Supplementary Protection Certificates for COMETRIQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2213661	PA2014033	Lithuania		PRODUCT NAME: CABOZANTINIBUM; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321
2213661	CR 2014 00039	Denmark		PRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140326
2213661	122014000091	Germany		PRODUCT NAME: CABOZANTINIB UND JEDES THERAPEUTISCHE AEQUIVALENT HIERVON WIE DURCH DAS GRUNDPATENT GESCHUETZT, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140321
2213661	300678	Netherlands		PRODUCT NAME: CABOZANTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326

COMETRIQ (cabozantinib) – Investment Analysis, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

COMETRIQ (cabozantinib) is an oral multikinase inhibitor marketed by Exelixis Inc., primarily indicated for the treatment of advanced renal cell carcinoma (RCC) and medullary thyroid carcinoma (MTC). Since its FDA approval in 2016, it has established a significant foothold within targeted oncology therapeutics, driven by its unique mechanism of inhibiting MET, VEGFR2, and other kinases involved in tumor progression.

This analysis evaluates COMETRIQ’s current market landscape, its growth prospects, risks, and projected financial trajectory. Emphasis is placed on sales performance, competition, regulatory influences, and potential pipeline developments relevant to investment decisions.

---

1. Investment Scenario Overview

Aspect	Details
Market Position	Leading targeted therapy in specific cancer subtypes with a well-established sales profile since 2016.
Current Valuation (as of 2023)	Approx. $2.4 billion market capitalization (Exelixis), with COMETRIQ contributing a significant revenue stream.
Key Drivers	Rising RCC and MTC incidence, expanding clinical uses, combination therapy potential.
Main Risks	Patent expirations, generic competition, biosimilars, emerging pipeline drugs, regulatory developments.

Financial Highlights (FY2022):

Metric	Value	Source
Net Sales (COMETRIQ)	~$270 million	Exelixis FY2022 Financial Reports
Gross Margin	~75%	Assumed from standard oncology drug profiles
R&D Spend	~$150 million	FY2022 overall R&D, specific to oncology pipeline

---

2. Market Dynamics Analysis

a) Indication-specific Market Size and Growth

Indication	Market Size 2022 (USD)	CAGR (2022-2027)	Main Players	Key Factors Driving Growth
Advanced Renal Cell Carcinoma	~$4.1 billion	7.3%	Tecentriq (Roche), Keytruda (Merck), Bavencio	Rising RCC incidence, targeted therapies adoption
Medullary Thyroid Carcinoma	~$540 million	5.2%	Vandetanib, Lenvatinib	Rare, but stable demand due to limited options

Sources: Grand View Research, 2022; EvaluatePharma, 2023.

b) Competitive Landscape

Competitors	Drugs	Mechanism of Action	Market Share (%)	Strategic Advantage
Roche	Tecentriq	PD-L1 inhibitor	35% (RCC)	First-mover advantage, combination trials
Merck	Keytruda	PD-1 inhibitor	25%	Extensive clinical pipeline, global reach
Bayer	Cabometyx, Lenvatinib	Multikinase	12%	Strong pipeline, coexistence with COMETRIQ in RCC; eventual biosimilar threat
Exelixis	COMETRIQ	Multikinase	Approx. 10-15% sales share	Pioneering targeted kinase inhibition

Note: COMETRIQ faces competition primarily from immunotherapies, with combination strategies increasingly prevalent.

c) Regulatory and Policy Environment

• FDA Approvals & Label Expansion: Minor updates since initial approval, with ongoing research into combination regimens.
• Pricing & Reimbursement: Favorable in key markets due to clinical benefit, but pricing pressures from payers persist.
• Patent and Market Exclusivity: Patents extend until around 2030, with some biosimilar entries anticipated post-2030.

---

3. Financial Trajectory and Forecast

a) Revenue Projections (2023-2028)

Year	Estimated COMETRIQ Sales (USD millions)	Assumptions
2023	~$290	Moderate growth driven by RCC incidence
2024	~$315	New combination trials positive impact
2025	~$330	Market saturation, pipeline contributes
2026	~$350	Emerging biosimilars, slight dip forecasted
2027	~$370	New label indications, broad geographic expansion
2028	~$390	Pipeline success, expanded indications

Growth rate assumption: CAGR of 8% till 2026, tapering to 5% post-2026.

b) Impact of Pipeline Developments

• Combination Therapy Trials: Ongoing studies with immunotherapies may enhance label utility.
• New Indications & Formulations: Any successful expansion could add 10-15% to peak revenues.
• Biosimilar Entries: Potential for revenue decline by 2028 if biosimilars penetrate markets.

c) Profitability and Margins

Metric	2022 Actual	Forecast (2028)	Notes
Gross Margin	~75%	~70-72%	Slight reduction due to biosimilar price erosion
Operating Margin	~30%	~28-30%	R&D costs may increase with pipeline expenses
Net Income	~$81 million	~$110 million	Reflecting revenue growth and margin stability

---

4. Comparative and Sensitivity Analysis

Variable	Impact on Revenue	Scenario	Notes
Patent Expiry	Potential 15-20% decline	Base	Expected around 2030
Launch of Biosimilars	25-30% decline	Bear	Post-2028 entry, depending on market absorption
Pipeline Success Rate	Up to 10-15% boost	Optimistic	Successful Phase III results

Sensitivity reflects the potential impact of regulatory, scientific, and market dynamics on COMETRIQ's future revenue trajectory.

---

5. Investment Risks and Opportunities

Risks	Opportunities
Patent expiration (2029-2030)	Early pipeline development, biosimilar market strategy
Emerging biosimilars	Diversification into novel MOAs
Market saturation	Expansion into combinatory therapies
Pricing regulations	Advocacy for value-based reimbursement models
Clinical pipeline	Potential new approvals; regenerative therapies

---

6. Comparative Financial Metrics Against Peers

Company	Market Cap (USD bn)	Focus	Peak Revenue (USD mn)	R&D Spend (USD mn)	Patent Expiry (year)
Exelixis	2.4	Oncology, kinase inhibitors	~$370 (2028 forecast)	~$150 (2022)	2030 (patents)
Roche	263	Broad oncology portfolio	Several billion	Significant R&D	2028-2032 (various patents)
Merck	205	Immuno-oncology	3-4 billion (Keytruda)	1.9 billion (2022)	2027-2030

---

7. Regulatory and Policy Impacts on Investment Outlook

• Regulatory agencies increasingly favor combination therapy approvals for oncology.
• Pricing pressures are intensifying globally, impacting profit margins.
• Patent protections remain critical; biosimilar threats accelerate post-2030.

---

Key Takeaways

• Market Position: COMETRIQ maintains a solid position within RCC and MTC segments, with revenues expected to grow modestly until patent expiration.
• Growth Drivers: Incidence rise, therapy diversification, and combination therapies.
• Risks: Patent expiry (~2030), biosimilar competition, and regulatory pricing pressures could diminish revenues.
• Pipeline Potential: Positive clinical trial developments in combination protocols could boost future sales.
• Financial Outlook: Revenues projected to grow at CAGR ~6-8% until 2026, with margins likely stable but susceptible to biosimilar entry.

---

FAQs

Q1: How long will COMETRIQ retain market exclusivity?
A1: Patent protections extend until approximately 2030, after which biosimilar competition may impact sales.

Q2: What are major competitors to COMETRIQ?
A2: Key competitors include immunotherapies like Tecentriq (Roche), Keytruda (Merck), and other kinase inhibitors like Lenvatinib.

Q3: Can COMETRIQ expand into new indications?
A3: Potential exists via ongoing clinical trials, including combinations with immunotherapies; success could enhance revenue streams.

Q4: How do biosimilars affect COMETRIQ's long-term potential?
A4: Biosimilar entries could reduce market share and pricing power post-2028, especially after patent expiry.

Q5: What regulatory trends could influence COMETRIQ's future?
A5: Favorable approvals for combination regimens and streamlined pathways could open new market opportunities; however, pricing regulations pose risk.

---

References

[1] Exelixis Inc. FY2022 Financial Reports
[2] Grand View Research, 2022: Market Size & Growth for RCC & MTC
[3] EvaluatePharma, 2023: Oncology Drug Market Analysis
[4] FDA Drug Approvals Database
[5] Industry Reports on Biosimilar Market Penetration